{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 24.', '9.5.7.12 Week 24', 'Week 24 is the final visit of the Treatment Period. Study drug is not administered.', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis (see Section 9.5.5.7 for details concerning test results and study', 'participation).', 'Collect urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential.', 'Collect blood sample for biomarker analyses.', 'Collect blood sample for immunogenicity testing (only subjects who complete the', 'Treatment Period, not those who prematurely discontinue study drug administration).', 'Collect blood sample for PK analysis (only subjects who complete the Treatment Period,', 'not those who prematurely discontinue study drug administration).', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform 12-lead ECG.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Measure weight.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Contact IWRS to register the End-of-Treatment Visit.', 'Subjects will be discharged from the study center after all of the procedures have been', 'completed.', 'Subjects who are proptosis non-responders will be offered the opportunity to receive 8 infusions', 'of teprotumumab in an open-label extension study, HZNP-TEP-302.', 'Subjects who are proptosis responders and those who are non-responders and do not elect to', 'participate in the open-label extension study will enter the Follow-Up Period and will be', 'instructed to return to the clinic in 4 weeks for the first follow-up visit.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 99 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.7.13 Week 28', 'Collect urine sample for a pregnancy test for females of childbearing potential.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect vital signs.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 36.', '9.5.7.14 Week 36', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis.', 'Collect urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect blood sample for immunogenicity testing.', 'Collect vital signs.', 'Measure weight.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 48.', '9.5.7.15 Week 48', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Measure weight.', 'Administer GO-QoL questionnaire.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 100 of 117']\n\n###\n\n", "completion": "END"}